Andre the Giant and Acromegaly: How a Regular Patient Gets Diagnosed and Treated Today

Andre the Giant's Untreated Acromegaly: A Historical Case

Andre the Giant stood approximately 7 feet 4 inches tall and weighed over 500 pounds at his peak. His extraordinary size was not genetic variation or nutritional abundance. It was the result of acromegaly, a condition driven by a GH-secreting pituitary adenoma that was never surgically addressed during his lifetime.

What Caused Andre's Condition

Acromegaly results from sustained overproduction of growth hormone, almost always by a benign pituitary tumor (adenoma). When GH excess begins before epiphyseal plate closure in childhood, the result is gigantism, which is what Andre experienced. GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), and chronically elevated IGF-1 drives the soft tissue enlargement, skeletal overgrowth, and organ hypertrophy that define the disease [1].

Andre reportedly refused treatment throughout his life. By the 1980s, his mobility had deteriorated significantly, and he required a back brace for wrestling appearances. His heart, enlarged from years of GH excess (a condition called acromegalic cardiomyopathy), ultimately failed. He died in his sleep in a Paris hotel room on January 27, 1993 [2].

Why He Was Never Treated

The treatment field in Andre's era was far more limited. Transsphenoidal surgery existed but carried higher complication rates than it does today. Somatostatin analogs were not commercially available until octreotide received FDA approval in 1988, by which point Andre's disease had progressed for over four decades [3]. There is no public record of any physician offering or Andre accepting surgical intervention for his pituitary tumor.

How Acromegaly Is Diagnosed in 2026

A patient presenting with symptoms similar to Andre's would enter a structured diagnostic pathway that, despite its clarity on paper, still averages 7 to 10 years from first symptom to confirmed diagnosis. The Endocrine Society's 2014 clinical practice guideline (reaffirmed in subsequent updates) outlines the standard workup [4].

Initial Clinical Suspicion

The earliest signs of acromegaly are often subtle. Patients notice that rings no longer fit, shoes feel tight, or facial features appear coarser over time. Dentists sometimes detect mandibular prognathism (jaw protrusion) before physicians suspect the diagnosis. Other common presentations include excessive sweating, joint pain, sleep apnea, and carpal tunnel syndrome.

Biochemical Confirmation

The screening test is a serum IGF-1 level, measured against age- and sex-matched reference ranges. If IGF-1 is elevated, the confirmatory test is an oral glucose tolerance test (OGTT) with serial GH measurements. In healthy individuals, a 75-gram oral glucose load suppresses GH below 0.4 µg/L. In acromegaly, GH fails to suppress below 1 µg/L (some guidelines use a 0.4 µg/L cutoff with newer ultrasensitive assays) [4].

Imaging

Once biochemical acromegaly is confirmed, pituitary MRI with gadolinium contrast identifies the adenoma. Approximately 75% of GH-secreting adenomas are macroadenomas (≥10 mm in diameter) at the time of diagnosis, reflecting the long diagnostic delay [5]. Microadenomas (<10 mm) carry a substantially better surgical prognosis.

Transsphenoidal Surgery: The First-Line Treatment

For the vast majority of acromegaly patients in 2026, the first treatment offered is transsphenoidal adenomectomy, a minimally invasive procedure that approaches the pituitary through the nasal passages and sphenoid sinus.

Surgical Success Rates

Biochemical remission rates depend heavily on tumor size and surgeon experience. In a meta-analysis of 7,648 patients across 47 studies, biochemical remission occurred in 75 to 95% of microadenomas and 40 to 68% of macroadenomas [6]. The Endocrine Society guideline recommends that surgery be performed by a high-volume pituitary surgeon (defined as performing at least 50 transsphenoidal procedures per year), since outcomes correlate directly with operative volume [4].

What "Remission" Means

Surgical remission is defined as normalization of serum IGF-1 for age and sex, plus either a random GH level below 1.0 µg/L or GH nadir below 0.4 µg/L on OGTT. These benchmarks are reassessed at 12 weeks post-surgery [4]. Patients who achieve remission have mortality rates that return to baseline population levels. A 2008 meta-analysis by Holdaway et al. Demonstrated that patients with a post-treatment GH level below 2.5 µg/L had a standardized mortality ratio (SMR) of 1.1, compared to an SMR of 1.9 in those with GH above 2.5 µg/L [7].

Surgical Complications

Modern transsphenoidal surgery carries a low complication rate in experienced hands. Transient diabetes insipidus occurs in 5 to 15% of cases. Permanent diabetes insipidus, CSF leaks requiring repair, and new anterior pituitary hormone deficiencies each occur in fewer than 5% of patients [6]. Andre's era lacked the endoscopic visualization, intraoperative MRI, and neuronavigation tools that make today's procedures safer.

Medical Therapy When Surgery Is Not Enough

Roughly 30 to 60% of macroadenoma patients do not achieve remission from surgery alone. These patients, and those who are poor surgical candidates, receive medical therapy.

Somatostatin Receptor Ligands (SRLs)

Octreotide LAR (long-acting release) and lanreotide Autogel are the two first-generation somatostatin analogs used as first-line medical therapy. Both bind somatostatin receptor subtype 2 (SSTR2) on the pituitary adenoma, suppressing GH secretion. Octreotide LAR is administered as a 20 to 30 mg intramuscular injection every 4 weeks. Lanreotide Autogel is a 60 to 120 mg deep subcutaneous injection every 4 weeks [8].

In clinical trials, first-generation SRLs normalize IGF-1 in approximately 55% of patients. The PRIMARYS trial (N=90) showed that lanreotide Autogel 120 mg achieved tumor volume reduction of ≥20% in 63% of treatment-naive patients at 48 weeks [9].

Pasireotide LAR, a second-generation SRL that binds somatostatin receptor subtypes 1, 2, 3, and 5, is reserved for patients who do not respond adequately to first-generation SRLs. In the PAOLA trial (N=198), pasireotide LAR achieved biochemical control in 15.4% of patients with inadequate response to octreotide or lanreotide, versus 0% in the continued first-generation SRL arm [10]. The trade-off is a high rate of hyperglycemia: 57% of pasireotide-treated patients developed elevated fasting glucose or required antidiabetic medication.

Pegvisomant: The GH Receptor Antagonist

Pegvisomant (Somavert) works differently from SRLs. Rather than suppressing GH secretion at the pituitary, it blocks GH action at the receptor in peripheral tissues, directly lowering IGF-1. In the key registration trial (N=112), pegvisomant normalized IGF-1 in 97% of patients at 20 mg/day after 12 months [11].

Pegvisomant is typically reserved for patients who fail or cannot tolerate SRLs. It is administered as a daily subcutaneous injection, with doses ranging from 10 to 30 mg. Liver function tests must be monitored, as transaminase elevations above 3 times the upper limit of normal occur in approximately 2.5% of patients [11]. The ACROSTUDY post-marketing surveillance database, which has tracked over 2,000 patients, has confirmed long-term safety with no significant increase in pituitary tumor growth during pegvisomant monotherapy [12].

Combination Therapy

For patients who achieve partial responses, combining an SRL with pegvisomant can be effective. A study by Neggers et al. (N=141) showed that adding pegvisomant to long-acting octreotide normalized IGF-1 in 97.0% of combination-treated patients at a median pegvisomant dose of just 40 mg/week, substantially lower than the monotherapy dose [13].

Radiation Therapy: The Third-Line Option

When surgery and medical therapy together fail to control disease, stereotactic radiosurgery (Gamma Knife or CyberKnife) or fractionated stereotactic radiotherapy is considered.

Efficacy and Timeline

Radiation achieves biochemical remission in 40 to 60% of patients, but the effect is slow. The median time to biochemical remission after Gamma Knife radiosurgery is 3 to 5 years [14]. During this interval, patients continue medical therapy.

Hypopituitarism Risk

The primary long-term complication is hypopituitarism. Within 10 years of radiation, 20 to 80% of patients develop at least one new pituitary hormone deficiency, most commonly growth hormone deficiency (ironic, given the original disease), followed by gonadotropin, ACTH, and TSH deficiency [14]. These deficiencies require lifelong hormone replacement.

The Practical Access Pathway for a Patient in the United States

A person in 2026 who suspects they have acromegaly (or whose physician suspects it) would follow this sequence.

Step 1: Primary Care and Referral

The process begins with a primary care physician ordering a serum IGF-1 level. If elevated, the patient is referred to an endocrinologist for confirmatory testing (OGTT with GH) and pituitary MRI. Wait times for endocrinology referrals average 30 to 90 days depending on region and insurance type.

Step 2: Surgical Evaluation

After diagnosis, the endocrinologist refers the patient to a neurosurgeon with pituitary expertise. The Pituitary Society maintains a directory of experienced pituitary centers. Academic medical centers with established pituitary programs (such as those at Johns Hopkins, UCSF, Cedars-Sinai, and Massachusetts General Hospital) see the highest case volumes. Patients may need to travel for surgery if no high-volume center exists nearby.

Step 3: Insurance and Cost Considerations

Transsphenoidal surgery is covered by Medicare, Medicaid, and virtually all commercial insurance plans as a medically necessary procedure. Out-of-pocket costs depend on plan design but are typically limited to the surgical deductible and copay.

Medical therapy costs are more variable. Octreotide LAR carries a wholesale acquisition cost of approximately $3,500 to $4,800 per monthly injection. Lanreotide Autogel ranges from $3,200 to $5,100 per month. Pegvisomant is the most expensive option, at roughly $6,000 to $8,000 per month at typical doses [15]. Most insurers cover these medications with prior authorization. Manufacturer copay assistance programs (Novartis for octreotide and pasireotide; Ipsen for lanreotide; Pfizer for pegvisomant) can reduce out-of-pocket costs significantly.

Step 4: Lifelong Monitoring

Acromegaly requires indefinite follow-up. Post-surgical patients undergo IGF-1 and GH testing at 12 weeks, then every 6 to 12 months. Pituitary MRI is repeated annually for the first 3 years and then at longer intervals if stable. Colonoscopy screening is recommended because acromegaly increases colorectal neoplasm risk; the Endocrine Society recommends screening colonoscopy at diagnosis and repeat screening based on findings [4].

What Would Be Different for Andre Today

If Andre the Giant were born in 2000 instead of 1946, his trajectory would look fundamentally different.

Earlier Diagnosis

Pediatric endocrinologists now recognize accelerated linear growth velocity as a potential sign of GH excess. A child growing along the 99.9th percentile with other features (coarsened facial features, excessive sweating, large hands) would prompt an IGF-1 check. The diagnostic delay would likely be years rather than decades.

Surgical Intervention in Adolescence

Transsphenoidal surgery in adolescence could remove or debulk the adenoma before decades of GH excess caused irreversible skeletal and cardiac changes. Even a partial resection followed by SRL therapy would reduce GH exposure dramatically.

Cardiac Protection

Acromegalic cardiomyopathy (biventricular hypertrophy, diastolic dysfunction, and eventually systolic failure) develops over decades of GH excess. Colao et al. Demonstrated that 12 months of SRL therapy significantly improved left ventricular mass index and diastolic function in acromegaly patients [16]. Early treatment could have prevented or substantially delayed the congestive heart failure that killed Andre at 46.

Life Expectancy

With biochemical control, modern acromegaly patients have near-normal life expectancy. The Holdaway meta-analysis showed that patients achieving GH below 2.5 µg/L had no statistically significant excess mortality (SMR 1.1, 95% CI 0.9 to 1.4) [7]. Andre might well have lived into his 70s or 80s with appropriate treatment.

Dr. Shlomo Melmed, a leading pituitary researcher at Cedars-Sinai, has stated: "The goal of acromegaly treatment is biochemical remission, which translates directly into normalization of mortality risk. We now have the tools to achieve that goal in the majority of patients" [4].